Skip to main content
TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc. — Investor Relations & Filings

Ticker · TLSI ISIN · US58507N2045 US Professional, scientific and technical activities
Filings indexed 448 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country US United States of America
Listing US TLSI

About TriSalus Life Sciences, Inc.

https://trisaluslifesci.com/

TriSalus Life Sciences is an oncology company focused on developing treatments for solid tumors, particularly in the liver and pancreas. The company's therapeutic platform integrates its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology with investigational immunotherapies. This integrated approach is designed to overcome critical barriers to treatment, such as high intratumoral pressure and the immunosuppressive tumor microenvironment, which can limit the efficacy of cancer therapies. Key components of its platform include the TriNav® Infusion System for targeted drug delivery and the investigational immunotherapy candidate, nelitolimod. The company aims to improve patient outcomes by enhancing the delivery and effectiveness of treatments, often in combination with systemic immunotherapies.

Recent filings

Filing Released Lang Actions
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
Regulatory Filings
2026-04-29 English
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
Regulatory Filings
2026-04-07 English
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
Director's Dealing
2026-03-20 English
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
Director's Dealing
2026-03-20 English
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
Director's Dealing
2026-03-20 English
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
Director's Dealing
2026-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.